Towards an Effective Vaccine against Blood-Stage Plasmodium vivax Malaria. (360G-Wellcome-108734_Z_15_Z)

£271,399

Growing recognition of the huge morbidity and significant mortality attributable to Plasmodium vivax (P.vivax) malaria has led to renewed calls for an effective vaccine against this most widespread of the human malarias. The leading vaccine candidate antigen has long been the P.vivax Duffy-Binding Protein region II (PvDBP-RII) with which the parasite attaches to the Duffy antigen on the red blood cell membrane and enters the cell. This was put to the test last year in Oxford in the first human vaccine trial against blood-stage vivax malaria in which 24 volunteers were vaccinated with PvDBP_RII. PvDBP-RII does, however, show significant inter-strain polymorphism and this may jeopardise the vaccines' potential to induce strain transcending immunity A new and promising candidate antigen, the RH5-Ripr Membrane-Anchoring Protein (RRMAP), has recently been described. It is also essential for red cell entry and appears to be highly conserved. To assess the potential of these two antigens , I will produce monoclonal antibodies from the serum of the human PvDBP_RII vaccinees and raise rabbit antisera against RRMAP. I will then test and compare these antibodies in novel functional parasite invasion assays, progressing the most promising to detailed structural studies with my Co-Supervisor in the Department of Biochemistry.

Where is this data from?

This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.

Grant Details

Amount Awarded 271399
Applicant Surname Rawlinson
Approval Committee Clinical Interview Committee
Award Date 2015-06-24T00:00:00+00:00
Financial Year 2014/15
Grant Programme: Title Research Training Fellowship
Internal ID 108734/Z/15/Z
Lead Applicant Dr Thomas Rawlinson
Partnership Value 271399
Planned Dates: End Date 2018-09-30T00:00:00+00:00
Planned Dates: Start Date 2015-10-01T00:00:00+00:00
Recipient Org: Country United Kingdom
Region South East
Sponsor(s) Prof Simon Draper